Total Payments
$1,280
2024 Payments
$514.20
Companies
12
Transactions
70
Medicare Patients
6,766
Medicare Billing
$1.3M
Payment Breakdown by Category
Food & Beverage$1,120 (87.4%)
Education$160.77 (12.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,120 | 58 | 87.4% |
| Education | $160.77 | 12 | 12.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Vifor Pharma, Inc. | $677.06 | 40 | $0 (2024) |
| Travere Therapeutics, Inc. | $109.46 | 7 | $0 (2024) |
| Lilly USA, LLC | $96.18 | 3 | $0 (2024) |
| Genentech USA, Inc. | $81.26 | 5 | $0 (2018) |
| Otsuka America Pharmaceutical, Inc. | $70.62 | 3 | $0 (2024) |
| Ardelyx, Inc. | $61.83 | 2 | $0 (2024) |
| GlaxoSmithKline, LLC. | $48.38 | 3 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $46.39 | 3 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $29.44 | 1 | $0 (2024) |
| OPKO Pharmaceuticals, LLC | $22.50 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $514.20 | 24 | Travere Therapeutics, Inc. ($109.46) |
| 2023 | $404.38 | 21 | Vifor Pharma, Inc. ($385.90) |
| 2022 | $242.57 | 17 | Vifor Pharma, Inc. ($199.23) |
| 2021 | $27.54 | 2 | GlaxoSmithKline, LLC. ($27.54) |
| 2018 | $41.60 | 3 | Genentech USA, Inc. ($31.08) |
| 2017 | $50.18 | 3 | Genentech USA, Inc. ($50.18) |
All Payment Transactions
70 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $32.66 | General |
| Category: Diabetes | ||||||
| 12/05/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $31.19 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/05/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: Phosphate binder for ESRD | ||||||
| 12/03/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $19.89 | General |
| Category: NEPHROLOGY | ||||||
| 12/03/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: Hyperkalemia | ||||||
| 11/21/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $32.93 | General |
| Category: Diabetes | ||||||
| 11/18/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $27.64 | General |
| Category: NEPHROLOGY | ||||||
| 11/11/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: Hyperkalemia | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $29.44 | General |
| 10/22/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: Hyperkalemia | ||||||
| 10/16/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/10/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: Hyperkalemia | ||||||
| 09/30/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $23.09 | General |
| Category: NEPHROLOGY | ||||||
| 09/18/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/16/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $30.64 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/06/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $30.59 | General |
| Category: Diabetes | ||||||
| 08/29/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $35.92 | General |
| 08/29/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $30.85 | General |
| 08/29/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $2.38 | General |
| 08/01/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $16.89 | General |
| 08/01/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $2.38 | General |
| 07/09/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $3.08 | General |
| 05/06/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $17.96 | General |
| 01/22/2024 | Vifor Pharma, Inc. | — | Food and Beverage | In-kind items and services | $18.40 | General |
| 11/16/2023 | Vifor Pharma, Inc. | Veltassa (Drug), Korsuva | Food and Beverage | In-kind items and services | $14.14 | General |
| Category: Hyperkalemia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,392 | 2,609 | $961,497 | $276,528 |
| 2022 | 10 | 1,483 | 2,933 | $1.0M | $289,860 |
| 2021 | 13 | 1,816 | 3,618 | $1.3M | $371,702 |
| 2020 | 14 | 2,075 | 4,093 | $1.5M | $393,657 |
Total Patients
6,766
Total Services
13,253
Medicare Billing
$1.3M
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 406 | 974 | $190,979 | $57,975 | 30.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 471 | 678 | $218,523 | $56,554 | 25.9% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 74 | 206 | $182,841 | $52,721 | 28.8% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 37 | 165 | $120,912 | $36,258 | 30.0% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 65 | 160 | $117,835 | $33,974 | 28.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 108 | 112 | $48,675 | $14,653 | 30.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 92 | 101 | $33,493 | $9,895 | 29.5% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 104 | 168 | $30,109 | $9,072 | 30.1% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2023 | 19 | 23 | $11,650 | $3,450 | 29.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 16 | 22 | $6,482 | $1,976 | 30.5% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 87 | 267 | $242,169 | $68,524 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 498 | 755 | $247,640 | $62,850 | 25.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 400 | 1,141 | $205,380 | $61,571 | 30.0% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 98 | 241 | $180,991 | $52,373 | 28.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 186 | 211 | $71,951 | $21,545 | 29.9% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 99 | 169 | $31,096 | $9,375 | 30.1% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2022 | 23 | 32 | $16,448 | $4,780 | 29.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 26 | 28 | $14,028 | $4,220 | 30.1% |
| 90935 | Hemodialysis procedure with physician evaluation | Office | 2022 | 13 | 32 | $5,888 | $1,775 | 30.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 20 | $5,180 | $1,558 | 30.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 34 | 37 | $5,291 | $1,289 | 24.4% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 119 | 324 | $317,643 | $86,801 | 27.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 507 | 1,466 | $239,655 | $80,513 | 33.6% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 115 | 294 | $225,348 | $64,622 | 28.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 467 | 701 | $169,467 | $61,294 | 36.2% |
About Dr. Patrick Kulubya, M.D
Dr. Patrick Kulubya, M.D is a Nephrology healthcare provider based in Memphis, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720057714.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Kulubya, M.D has received a total of $1,280 in payments from pharmaceutical and medical device companies, with $514.20 received in 2024. These payments were reported across 70 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($1,120).
As a Medicare-enrolled provider, Kulubya has provided services to 6,766 Medicare beneficiaries, totaling 13,253 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Other Specialties Nephrology, Nephrology
- Location Memphis, TN
- Active Since 03/14/2006
- Last Updated 08/12/2010
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1720057714
Products in Payments
- Veltassa (Drug) $505.77
- JARDIANCE (Drug) $96.18
- Rituxan (Biological) $81.26
- Korsuva (Drug) $78.75
- JYNARQUE (Drug) $70.62
- IBSRELA (Drug) $61.83
- BENLYSTA (Biological) $48.38
- LOKELMA (Drug) $31.73
- RAYALDEE (Drug) $22.50
- Velphoro (Drug) $18.87
- TAVNEOS (Drug) $18.48
- FARXIGA (Drug) $14.66
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Memphis
Dr. Omar Davis, M.d, M.D
Nephrology — Payments: $57,405
Nephrology $57,405
Dr. Natarsha Grant, Md, MD
Nephrology — Payments: $34,340
Nephrology $34,340
Dr. Robert Canada, Md, MD
Nephrology — Payments: $21,903
Nephrology $21,903
Dr. Wael Hussein
Nephrology — Payments: $15,498
Nephrology $15,498
Minesh Pathak, M.d, M.D
Nephrology — Payments: $13,583
Nephrology $13,583
L Quarles, M.d, M.D
Nephrology — Payments: $12,060
Nephrology $12,060